Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803

Visit website

NEWS

Drug Development

Incyte’s Graft-Versus-Host Trial Fails to Meet Primary Endpoint

Company shares dropped almost 10% at the news.

January 3, 2020

2 min read

Mark Terry

Drug Development

Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.

November 18, 2019

33 min read

Tracy Lawton

BioCapital

Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J

As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.

November 1, 2019

6 min read

Mark Terry

Drug Development

Clinical Catch-Up: October 14-18

Last week was busy for clinical trial news. Here’s a look.

October 18, 2019

6 min read

Mark Terry

Orca-T showed positive pool results against GvHD.

Drug Development

Novartis and Incyte’s JAK Inhibitor Jakafi Successful Against Graft-Versus-Host Disease

The primary endpoint of the trial was improving overall response rate at Day 28 with Jakafi compared to the best available therapy.

October 16, 2019

2 min read

Mark Terry

Deals

For Sale (Or Not): 10 Top Takeover Targets in the Biopharma Industry

There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.

September 9, 2019

6 min read

Mark Terry

Bio NC

Clinical Catch-Up: August 25-30

Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.

August 30, 2019

6 min read

Mark Terry

Drug Development

In Extensive Clinical Tests, Olumiant Continues to Show Efficacy in Atopic Dermatitis

The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.

August 26, 2019

2 min read

Alex Keown

Business

BIO Roundup: Agenus, FDA, Merck’s Frazier and Much More

With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.

June 6, 2019

7 min read

Mark Terry

AWARDS